NASDAQ:DBTX Decibel Therapeutics (DBTX) Stock Price, News & Analysis → “The Stock Market’s Bull Run is Far from Over” -Barrons (From Vertical Research Advisory) (Ad) Free DBTX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$4.90▼$5.1150-Day Range$4.91▼$5.2352-Week Range$1.61▼$5.40Volume1.26 million shsAverage Volume122,002 shsMarket Capitalization$123.39 millionP/E RatioN/ADividend YieldN/APrice Target$5.25 Stock AnalysisStock Analysis Get Decibel Therapeutics alerts: Email Address Decibel Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside6.9% Upside$5.25 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.12) to ($1.39) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.15 out of 5 starsMedical Sector925th out of 938 stocksBiotechnology Industry33rd out of 35 stocks 1.0 Analyst's Opinion Consensus RatingDecibel Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.25, Decibel Therapeutics has a forecasted upside of 6.9% from its current price of $4.91.Amount of Analyst CoverageDecibel Therapeutics has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for DBTX. Previous Next 0.0 Dividend Strength Dividend YieldDecibel Therapeutics does not currently pay a dividend.Dividend GrowthDecibel Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DBTX. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Decibel Therapeutics this week, compared to 0 articles on an average week. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Decibel Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders35.60% of the stock of Decibel Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions69.59% of the stock of Decibel Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Decibel Therapeutics are expected to grow in the coming year, from ($2.12) to ($1.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Decibel Therapeutics is -1.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Decibel Therapeutics is -1.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDecibel Therapeutics has a P/B Ratio of 1.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… About Decibel Therapeutics Stock (NASDAQ:DBTX)Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. The company's product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. Its lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. The company is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts. As of September 25, 2023, Decibel Therapeutics, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc.Read More Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… DBTX Stock News HeadlinesMarch 28, 2024 | cnet.comBest Noise-Canceling Headphones Under $100 for 2024March 5, 2024 | nytimes.comNoise-Induced Hearing Loss in Kids Is a Growing Problem. Here’s How to Protect Little Ears.March 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!February 14, 2024 | nytimes.comSound Machines Aren’t Just for Sleep. Here’s How to Use Brown Noise to Focus at Work.November 17, 2023 | nytimes.comThe Best Noise-Cancelling HeadphonesSeptember 15, 2023 | seekingalpha.comDecibel Therapeutics' CVR Appears Around Fair ValueSeptember 12, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DBTX, CPRI, CEQP, ESTEAugust 31, 2023 | benzinga.comMoore Kuehn Encourages CTG, KLR, ZYNE, and DBTX Investors to Contact Law FirmMarch 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!August 13, 2023 | businesswire.comDECIBEL THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Decibel ...August 12, 2023 | msn.comHC Wainwright & Co. Downgrades Decibel Therapeutics (DBTX)August 11, 2023 | finance.yahoo.comBiotech Stock Roundup: SAGE, GRTX Plunge on Setback, REGN to Buy DBTX & More NewsAugust 11, 2023 | finanznachrichten.deDecibel Therapeutics, Inc.: Decibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate UpdateAugust 11, 2023 | finance.yahoo.comDecibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate UpdateAugust 11, 2023 | msn.comBaird downgrades Decibel to neutral to reflect Regeneron takeoverAugust 10, 2023 | msn.comBaird Downgrades Decibel Therapeutics (DBTX)August 10, 2023 | finance.yahoo.comDecibel Therapeutics, Inc. (NASDAQ:DBTX) surges 80%; private equity firms who own 41% shares profited along with institutionsAugust 9, 2023 | washingtonpost.comComplaints about airplane noise rise at Reagan National, DullesAugust 9, 2023 | msn.comRegeneron to acquire gene therapy developer Decibel for $4 per shareAugust 9, 2023 | msn.comDecibel Therapeutics (NASDAQ:DBTX) Skyrockets On Acquisition By RegeneronAugust 9, 2023 | benzinga.comShareholder Alert: Ademi LLP investigates whether Decibel Therapeutics, Inc. has obtained a Fair Price in its transaction with RegeneronAugust 9, 2023 | finance.yahoo.comRegeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss ProgramsJuly 21, 2023 | finance.yahoo.comDBTX - Decibel Therapeutics, Inc.June 22, 2023 | markets.businessinsider.comRobert W. Baird Reaffirms Their Buy Rating on Decibel Therapeutics (DBTX)June 6, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Decibel Therapeutics (DBTX)June 2, 2023 | finance.yahoo.comDecibel Therapeutics to Participate in the Upcoming Jefferies Healthcare ConferenceJune 1, 2023 | finance.yahoo.comDecibel Therapeutics to Present DB-020 Phase 1b Clinical Trial Data at the American Society of Clinical Oncology (ASCO) 2023 Annual MeetingSee More Headlines Receive DBTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Decibel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:DBTX CUSIPN/A CIK1656536 Webdecibeltx.com Phone617-370-8701FaxN/AEmployees68Year FoundedN/APrice Target and Rating Average Stock Price Target$5.25 High Stock Price Target$5.25 Low Stock Price Target$5.25 Potential Upside/Downside+6.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,010,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-84.03% Return on Assets-53.90% Debt Debt-to-Equity RatioN/A Current Ratio3.03 Quick Ratio3.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.28 per share Price / Book1.50Miscellaneous Outstanding Shares25,130,000Free Float16,182,000Market Cap$123.39 million OptionableNot Optionable Beta-0.43 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Laurence E. Reid Ph.D. (Age 59)Pres & CEO Comp: $742.98kMs. Anna Trask M.A. (Age 65)Exec. VP & Chief People Officer Comp: $481.23kMr. John J. Lee (Age 55)Exec. VP & Chief Devel. Officer Comp: $596.15kMr. M. Charles LibermanCo-Founder & Member of Scientific Advisory BoardDr. Gabriel CorfasCo-Founder & Member of Scientific Advisory BoardDr. Ulrich MüllerCo-Founder & Member of Scientific Advisory BoardDr. Albert S. B. Edge (Age 68)Co-Founder & Member of Scientific Advisory Board Mr. James B. Murphy (Age 66)Interim CFO, Principal Financial Officer & Principal Accounting Officer Ms. Elaine Cope M.B.A.VP of OperationsMr. Geoff HorwitzVP of Corp. Devel. & Head of Bus. Devel.More ExecutivesKey CompetitorsClearside BiomedicalNASDAQ:CLSDImmunicNASDAQ:IMUXMediWoundNASDAQ:MDWDCarisma TherapeuticsNASDAQ:CARMCoya TherapeuticsNASDAQ:COYAView All Competitors DBTX Stock Analysis - Frequently Asked Questions Should I buy or sell Decibel Therapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Decibel Therapeutics in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DBTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DBTX, but not buy additional shares or sell existing shares. View DBTX analyst ratings or view top-rated stocks. What is Decibel Therapeutics' stock price target for 2024? 2 brokerages have issued 1-year target prices for Decibel Therapeutics' shares. Their DBTX share price targets range from $5.25 to $5.25. On average, they expect the company's share price to reach $5.25 in the next year. This suggests a possible upside of 6.9% from the stock's current price. View analysts price targets for DBTX or view top-rated stocks among Wall Street analysts. How were Decibel Therapeutics' earnings last quarter? Decibel Therapeutics, Inc. (NASDAQ:DBTX) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.23. When did Decibel Therapeutics IPO? Decibel Therapeutics (DBTX) raised $100 million in an IPO on Friday, February 12th 2021. The company issued 5,900,000 shares at $16.00-$18.00 per share. Citigroup, BMO Capital Markets, SVB Leerink and Barclays served as the underwriters for the IPO. This page (NASDAQ:DBTX) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Decibel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.